End-Stage Renal Disease Market Size, Share & Trends Analysis Report By Treatment (Transplant, Dialysis), By Diagnosis (Blood Test, Urine Test, Imaging Test, Others), By End-User (Hospitals and Clinics, Dialysis Centers, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

End-Stage Renal Disease Market Size

The global end-stage renal disease market size was valued at USD 119.74 billion in 2024 and is projected to reach USD 135.87 billion in 2025 to USD 373.41 billion by 2033, growing at a CAGR of 13.47% during the forecast period (2025-2033).

Factors like the rising prevalence of chronic kidney disease (CKD), increased awareness of early detection of ESRD, and improved access to healthcare in developing countries are expected to drive the global end-stage renal disease market. Furthermore, technological advancements in renal replacement therapies to enhance their treatment efficiency are estimated to create opportunities for global market growth.

End-stage renal disease (ESRD) is the final, most severe stage of chronic kidney disease (CKD), where the kidneys lose nearly all their ability to function effectively. This critical condition results in the kidneys being unable to filter waste and excess fluids from the blood, leading to dangerous levels of toxins and fluid accumulation in the body. The primary causes of ESRD include diabetes, high blood pressure, and other chronic conditions that damage the kidneys over time.

Symptoms of ESRD can include fatigue, swelling in the legs and feet, shortness of breath, and persistent nausea. Treatment options for ESRD are limited to dialysis, a procedure that artificially removes waste and extra fluid from the blood, or a kidney transplant. Managing ESRD requires comprehensive medical care, lifestyle changes, and regular monitoring to improve quality of life and mitigate complications.

Top 4 Key Highlights

• Dialysis dominates the treatment segment
• Blood tests dominate the diagnosis segment
• Hospitals and Clinics dominate the end-user segment.
• Asia-Pacific is the highest shareholder in the global market

End-Stage Renal Disease Market Drivers

Increasing prevalence of chronic kidney disease (CKD)

The rising incidence of chronic kidney disease (CKD) globally is a primary driver of the end-stage renal disease (ESRD) market. As of 2023, the global prevalence of CKD is estimated to be around 9.1% of the global population, which translates to approximately 700 million people affected worldwide. The surging aging population, which is more susceptible to CKD, further exacerbates this trend.

In the United States alone, the Centers for Disease Control and Prevention (CDC) reported that approximately 15% of adults, or 37 million people, have CKD. This increase in CKD cases directly translates to a higher number of ESRD cases, as CKD is a significant risk factor for ESRD. The demand for dialysis, kidney transplants, and other ESRD treatments is rising, boosting the market's growth. Additionally, the lack of widespread awareness and preventive measures for CKD contributes to its progression to ESRD, thereby driving market demand for advanced renal care solutions.

Market Restraining Factors

High cost of treatment and limited access to healthcare

The high cost of ESRD treatment poses a significant restraint on the market. Dialysis and kidney transplantation are expensive, long-term treatments that impose a substantial financial burden on patients and healthcare systems. According to the United States Renal Data System (USRDS), the annual per-person cost of hemodialysis is approximately $90,000, while the cost of a kidney transplant can exceed $400,000, including pre- and post-transplant care. These costs are often prohibitive, especially in low- and middle-income nations where healthcare resources are limited.

Additionally, limited access to healthcare facilities and trained medical professionals in rural and underdeveloped regions further hampers the market growth. In many parts of Africa and Asia, for instance, the lack of dialysis centers and nephrologists means that many patients do not receive timely and adequate treatment, leading to higher mortality rates. This disparity in access to treatment highlights the need for policies that can subsidize costs and improve healthcare infrastructure globally.

Market Opportunities

Technological advancements in renal replacement therapies

Technological innovations in renal replacement therapies, such as hemodialysis, peritoneal dialysis, and kidney transplantation, are significantly propelling the ESRD market. Recent advancements include wearable and portable dialysis machines, which offer greater flexibility and improve the quality of life for ESRD patients. For instance, the development of the Wearable Artificial Kidney (WAK) by the University of Washington has shown promising results in clinical trials, offering continuous dialysis in a compact, user-friendly device.

Furthermore, advancements in biocompatible dialysis membranes and improved dialysate solutions have enhanced the efficiency and safety of dialysis procedures. Innovations in kidney transplant techniques, such as robotic-assisted surgeries and advancements in immunosuppressive drugs, have increased the success rates of transplants and reduced the incidence of graft rejection. These technological strides not only improve patient outcomes but also create opportunities for market growth by making renal replacement therapies more accessible and effective.

Regional Insights

Asia Pacific is the most significant global market shareholder and is expected to expand substantially during the forecast period. The Asia-Pacific region is poised to be the fastest-growing market for end-stage renal disease (ESRD) due to several key factors. The region is experiencing a significant increase in the prevalence of diabetes and hypertension, which are the leading causes of chronic kidney disease (CKD) and, subsequently, ESRD. According to the International Diabetes Federation, the Asia-Pacific region houses approximately 60% of the global diabetic population, a trend that significantly contributes to the rising incidence of CKD and ESRD. Moreover, rapid urbanization and lifestyle changes in countries such as China, India, and Japan are exacerbating the burden of non-communicable diseases, including kidney diseases. In China, the prevalence of CKD is estimated to be around 10.8%, affecting approximately 119.5 million people, according to a study published in The Lancet. Similarly, India faces a significant burden with an estimated 17.2% prevalence of CKD, driven by high rates of diabetes and hypertension.

• The region is also witnessing substantial improvements in healthcare infrastructure and increased government initiatives aimed at combating CKD and ESRD. For instance, the Indian government has launched the Pradhan Mantri National Dialysis Programme to provide free dialysis services to the poor, significantly enhancing access to renal replacement therapies. Additionally, the growing investments by healthcare companies in the region are facilitating the development and adoption of advanced dialysis and transplant technologies. Companies like Fresenius Medical Care and Baxter International are expanding their operations and introducing innovative products tailored to the needs of the local population. The increasing awareness about kidney health and the availability of advanced treatment options are expected to further propel the growth of the ESRD market in the Asia-Pacific region, making it a lucrative area for investment and development.

Europe End-Stage Renal Disease Market Trends

Europe holds a significant share of the global end-stage renal disease (ESRD) market, driven by a high prevalence of chronic kidney disease (CKD) and advanced healthcare systems. Countries like Germany, France, the UK, and Italy have robust healthcare infrastructures and substantial investments in medical research and kidney care technologies. According to the European Renal Association, approximately 3.2 million people in Europe are affected by CKD, with a significant portion progressing to ESRD.

• The region is characterized by a high adoption rate of innovative dialysis technologies and kidney transplant procedures. Germany leads in the number of dialysis centers and kidney transplants, supported by comprehensive healthcare policies and reimbursement schemes. The European Union's initiatives, such as the Horizon Europe program, aim to boost research and innovation in renal care, further propelling market growth. However, disparities in healthcare access across different European countries pose a challenge. Southern and Eastern European countries, in particular, face limited resources and lower healthcare expenditure, impacting the overall regional growth potential.

Treatment Insights

The market is segmented into transplant and dialysis. The dialysis segment dominated the market during the forecast period. The demand for dialysis is rising due to the growing prevalence of end-stage renal disease (ESRD), driven by an increase in diabetes, hypertension, and chronic kidney disease alongside an aging population. According to the International Diabetes Federation, around 783 million people globally are expected to have diabetes by 2022, underscoring the need for dialysis as chronic kidney disease often progresses to ESRD. Additionally, investments by governments, healthcare organizations, and private providers in expanding dialysis centers and enhancing infrastructure have improved access to dialysis treatments. This expanded access has significantly contributed to the increased demand. Technological advancements, such as high-flux membranes, enhanced dialysis machines, and home-based dialysis options, have made treatments more effective, efficient, and convenient, improving patient outcomes and comfort. These innovations have further driven the demand for dialysis, solidifying its role as a critical treatment option in managing ESRD.

Diagnosis Insights

The market is segmented into blood tests, urine tests, imaging tests, and others. Blood tests held the largest share of the market over the forecast period. Blood tests play a pivotal role in diagnosing and monitoring end-stage renal disease (ESRD). They serve as crucial tools for early detection and ongoing assessment of kidney health. Serum creatinine and estimated glomerular filtration rate (eGFR) are primary indicators used to identify impaired kidney function. Additionally, tests like blood urea nitrogen (BUN) and electrolyte panels are routinely employed to monitor renal health in individuals with known kidney disease or ESRD. These tests provide essential insights into the progression of kidney dysfunction, assess the effectiveness of treatment protocols, and help in the early detection of potential complications. With growing awareness about kidney health, more individuals are opting for regular blood screenings to preemptively detect any signs of renal impairment. By facilitating timely interventions and personalized care strategies, these blood tests significantly contribute to improving outcomes and quality of life for patients managing ESRD globally.

End-User Insights

The market is segmented into hospitals and clinics, dialysis centers, and others. Hospitals and clinics dominate the end-user segment. Hospitals and clinics are pivotal in the management of end-stage renal disease (ESRD), offering essential services like hemodialysis, peritoneal dialysis, and kidney transplantation. They house specialized departments like nephrology and urology staffed with expert healthcare professionals trained in ESRD care. These departments are equipped with advanced infrastructure and technology for accurate diagnosis and effective treatment of ESRD patients. Dialysis units within hospitals provide both in-center hemodialysis and home-based dialysis options, catering to diverse patient needs. Additionally, hospitals serve as hubs for comprehensive care, integrating medical, surgical, and supportive services essential for managing ESRD complications. Their role extends beyond treatment to include patient education, ongoing monitoring, and support for transplantation candidates. In essence, hospitals are crucial in the global ESRD market, ensuring that patients receive specialized care and access to life-sustaining treatments that enhance quality of life and longevity.

Recent Developments

• March 2024- Bayer Healthcare, in collaboration with LASCO Pharmaceutical Division, launched finerenone, marketed as Firialta, to treat chronic kidney disease. The medicine prevents inflammation, reduces fibrosis, and decreases the amount of albumin (a protein whose presence in urine indicates kidney disease) in people suffering from renal disease.
• February 2024- the Central Drugs Standard Control Organisation (CDSCO) granted Jardiance (empagliflozin) 10 smg tablets to decrease the risk of long-term decline in patients with end-stage kidney disease, cardiovascular death, and hospitalization in adult individuals with chronic kidney disease (CKD), who are at risk of progression.